
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 5, 2006

ResMed Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction of
Incorporation)

001-15317
(Commission
File Number)

98-0152841
(I.R.S. Employer
Identification No.)

14040 Danielson Street
Poway, California 92064-6857
(Address of Principal Executive Offices) (Zip Code)

(858) 746-2400
(Registrant's telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 2.04. Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.

On January 5, 2006, ResMed Inc. (the "Company") announced that it has exercised its right to call for an early redemption all of its outstanding 4% Convertible Subordinated Notes due 2006. As of January 5, 2006, there was \$113.25 million in aggregate principal amount of the notes outstanding. The notes were issued and the redemption will be effected pursuant to the provisions of the Indenture dated June 20, 2001, between the Company and American Stock Transfer & Trust Company, as trustee. The Company provided notice to the trustee and the holders of the notes that it will redeem the notes on March 3, 2006 at a redemption price of approximately \$1,016 per \$1,000 principal amount of notes, or 100.8% of the principal amount thereof plus accrued and unpaid interest to the redemption date.

On the redemption date, the redemption price will become due and payable upon each note to be redeemed. Interest on the notes will cease to accrue on and after the redemption date and the only remaining right of the holders of the notes will be to receive payment of the redemption price, including accrued and unpaid interest to the redemption date, upon surrender to the trustee of the notes.

Pursuant to the Indenture, the notes called for redemption may be converted at the election of the holders into shares of common stock of the Company at any time before the close of business on March 2, 2006, the business day prior to the redemption date. The notes are convertible into approximately 33 shares of common stock of the Company for each \$1,000 principal amount of the notes, at a conversion price of \$30.30 per share. No payment will be made for accrued interest on notes surrendered for conversion.

A copy of the press release dated January 5, 2006 relating to the redemption is attached as Exhibit 99.1 hereto and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits

<u>Exhibits:</u>	<u>Description of Document</u>
99.1	Press Release dated January 5, 2006

SIGNATURES

We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

Date: January 11, 2006

RESMED INC.

(registrant)

By: /s/ David Pendarvis

Name: David Pendarvis

Its: Global General Counsel; Sr. Vice President,
Organizational Development; and Corporate Secretary

EXHIBIT INDEX

<u>Exhibits:</u>	<u>Description of Document</u>
99.1	Press Release dated January 5, 2006

ResMed Announces Early Redemption of 4% Convertible Notes

SAN DIEGO, California, January 5, 2006 – ResMed Inc (NYSE: RMD) today announced that it has exercised its right to call for an early redemption of all of its outstanding 4% convertible subordinated notes due June 20, 2006. Convertible notes in an aggregate principal amount of \$113.25 million are currently outstanding. The redemption price is approximately \$1,016 per \$1,000 principal amount of notes, including accrued interest through the early redemption date of March 3, 2006.

Note holders may elect to convert the notes into ResMed shares of common stock at any time until 5:00 PM Eastern Time on Thursday, March 2, 2006. The notes are convertible into approximately 33 ResMed shares for each \$1,000 principal amount of bonds, at a conversion price of \$30.30 per share. No payment will be made for accrued interest on notes surrendered for conversion.

ResMed would issue an aggregate of approximately 3.74 million shares if all currently outstanding notes were converted. The dilutive impact of these conversions has already been reflected in ResMed's reported diluted net income per share in accordance with US generally accepted accounting principles.

For assistance with redemption or conversion, please contact American Stock Transfer Shareholder Services at (800) 937-5449.

About ResMed

ResMed is a leading manufacturer of medical equipment for the treatment and management of sleep-disordered breathing and other respiratory disorders. We are dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Contact:

Hillary Theakston
Director of Investor Relations
(858) 746-2610
hillaryt@resmed.com